S&CO Inc. Has $1.48 Million Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Key Points

• S&CO Inc. increased its holdings in Elanco Animal Health by 17.7%, owning 141,284 shares valued at approximately $1.48 million as of the first quarter.
• Several institutional investors, including FMR LLC, significantly increased their stakes in Elanco Animal Health, with FMR LLC growing its stake by 1,153.6% in the fourth quarter.
• Elanco Animal Health's stock received positive analyst ratings, with UBS Group raising its target price from $17.00 to $18.00 and maintaining a "buy" rating.

S&CO Inc. lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 17.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 141,284 shares of the company's stock after acquiring an additional 21,284 shares during the quarter. S&CO Inc.'s holdings in Elanco Animal Health were worth $1,483,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Allworth Financial LP increased its holdings in shares of Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after buying an additional 2,090 shares during the last quarter. CoreCap Advisors LLC purchased a new stake in shares of Elanco Animal Health during the 4th quarter worth $29,000. NBC Securities Inc. purchased a new stake in Elanco Animal Health in the first quarter valued at $40,000. Parallel Advisors LLC lifted its position in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after acquiring an additional 1,852 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after buying an additional 1,740 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

Shares of ELAN traded up $0.12 during mid-day trading on Friday, hitting $13.80. The company's stock had a trading volume of 4,484,873 shares, compared to its average volume of 5,285,665. The firm has a 50-day moving average price of $14.11 and a 200 day moving average price of $11.96. The stock has a market capitalization of $6.85 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.75 and a beta of 1.67. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $15.78.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.06. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The firm's quarterly revenue was down 1.0% compared to the same quarter last year. During the same period last year, the firm posted $0.34 earnings per share. On average, research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target on the stock in a report on Thursday, July 17th. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Stifel Nicolaus upped their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Finally, Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.